13059_2020_2152_MOESM1_ESM.pdf (30.97 MB)
0/0

Additional file 1 of Cancer-specific CTCF binding facilitates oncogenic transcriptional dysregulation

Download (30.97 MB)
journal contribution
posted on 16.09.2020 by Celestia Fang, Zhenjia Wang, Cuijuan Han, Stephanie L. Safgren, Kathryn A. Helmin, Emmalee R. Adelman, Valentina Serafin, Giuseppe Basso, Kyle P. Eagen, Alexandre Gaspar-Maia, Maria E. Figueroa, Benjamin D. Singer, Aakrosh Ratan, Panagiotis Ntziachristos, Chongzhi Zang
Additional file 1: Fig. S1. Identification of cancer-specific CTCF binding sites. Fig. S2. Characterization of cancer-specific lost/gained CTCF binding sites. Fig. S3. Cancer-specific lost/gained CTCF binding sites associate with changed chromatin accessibility in patients. Fig. S4. Cancer-specific lost/gained CTCF binding sites associate with changed local chromatin interactions in different scales. Fig. S5. Lost/gained CTCF binding events associate with chromatin dynamics regardless of CTCF motif. Fig. S6. Histone modification patterns at cancer-specific lost and gained CTCF binding sites. Fig. S7. Histone modification patterns in normal CD4+ T-cell, T-ALL cell lines and T-ALL patients at T-ALLlost and T-ALLgained CTCF binding sites. Fig. S8. Cancer-specific loss/gain of CTCF events correlate with gene expression. Fig. S9. Patterns of differential DNA methylation near cancer-specific lost and gained CTCF sites with and without CTCF motif. Fig. S10. CTCF binding loss/gain events in T-ALL cell lines and T-ALL patients do not associate with DNA sequence mutations. Fig. S11. CTCF binding loss/gain events in 5 cancer types do not associate with DNA sequence mutations observed in ICGC samples. Fig. S12. Mutation rates around lost/gained CTCF binding sites in 6 cancer types. Fig. S13. Sequence motif analysis on cancer-specific lost and gained CTCF binding sites. Fig. S14. Cancer-specific gained CTCF correlate with oncogenic transcription factor. Fig. S15. Hi-C interaction maps in T-ALL cell line Jurkat and CD4+ T-cell. Fig. S16. Cancer-specific gained CTCF binding sites correlate with oncogenic transcriptional activation. Fig. S17. Pathway and Gene Ontology analyses of the genes located in the same chromatin domain with gained/lost CTCF sites for each cancer.

Funding

National Cancer Institute National Institute of General Medical Sciences National Heart, Lung, and Blood Institute National Institutes of Health

History

Exports